Published in

Dove Press, Therapeutics and Clinical Risk Management, p. 139

DOI: 10.2147/tcrm.s35788

Links

Tools

Export citation

Search in Google Scholar

Clinical development of neridronate: potential for new applications

Journal article published in 2013 by Davide Gatti, Maurizio Rossini ORCID, Ombretta Viapiana, Luca Idolazzi, Silvano Adami
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Davide Gatti, Maurizio Rossini, Ombretta Viapiana, Luca Idolazzi, Silvano AdamiRheumatology Unit, Department of Medicine, University of Verona, Verona, ItalyAbstract: Neridronate is an aminobisphosphonate, licensed in Italy for the treatment of osteogenesis imperfecta (OI) and Paget's disease of bone (PDB). A characteristic property of neridronate is that it can be administered both intravenously and intramuscularly, providing a useful system for administration in homecare. In this review, we discuss the latest clinical results of neridronate administration in OI and PDB, as well as in osteoporosis and other conditions. We will focus in particular on the latest evidence of the effect of neridronate on treatment of complex regional pain syndrome type I.Keywords: bisphosphonates, osteogenesis imperfecta, osteoporosis, complex regional pain syndrome